Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06331312 · ClinicalTrials.gov registry record · Phase 3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
A Phase 3 study of Polymyalgia Rheumatica, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT06331312: Recruiting Phase 3 study of Polymyalgia Rheumatica, sponsored by Novartis Pharmaceuticals.
NCT06331312 is a Phase 3 study of Polymyalgia Rheumatica that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 288 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06331312, a Phase 3 study of Polymyalgia Rheumatica, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Primary Outcome
The number and percentage of participants with treatment emergent AEs/SAEs will be summarized. No hypothesis testing will be performed.
Conditions Studied
Interventions
- BIOLOGICAL Secukinumab
Study Locations (20)
Florida
- Rheumatology Associates of South Florida - Boca Raton
- UF Health Cancer Center - Gainesville
- Sarasota Arthritis Res Ctr - Sarasota
- West Broward Rheumatology Associates Inc - Tamarac
California
- Orrin Troum MD and Medical Associates - Santa Monica
- Center for Rheumatology Research - West Hills
- Millennium Clinical Trials - Westlake Village
Texas
- Prolato Clinical Research Center - Houston
- Accurate Clinical Research Inc - San Antonio
- Advanced Rheumatology of Houston - Spring
Arizona
- Arizona Arthritis and Rheumatology Associates PLLC - Avondale
- Sun Valley Arthritis Center Ltd - Peoria
Georgia
- Arthritis Center of North Georgia - Gainesville
Maryland
- Klein and Associates - Hagerstown
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Clinical Research Inst of MI - Saint Clair Shores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2028-08-22 |
| Phase | Phase 3 |
What NCT06331312 shows while recruiting
NCT06331312 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Polymyalgia Rheumatica appearing as the primary indexed condition, and to 1 intervention - of which Secukinumab is the first listed.
NCT06331312 names 20 study sites across 12 states, led by Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06331312 about?
NCT06331312 is a clinical study titled "Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)". The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
What is the current status of trial NCT06331312?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2024-06-28. Estimated completion is 2028-08-22.
What conditions does trial NCT06331312 study?
This clinical trial studies the following conditions: Polymyalgia Rheumatica.
What interventions are being tested in trial NCT06331312?
The interventions under investigation include: Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06331312?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06331312 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polymyalgia Rheumatica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06331312's enrollment target sits among peer trials
288 1175th of 2000 higher than 819 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI